Skip to main content
. 2024 Oct 24;12(11):2439. doi: 10.3390/biomedicines12112439

Figure 7.

Figure 7

Immunomodulating therapies were differentially associated with overall survival in patients with or without fibrosis. Kaplan–Meier and Log-Rank tests for the overall survival (OS) of ILD patients according to the type of immunomodulatory treatment, corticosteroids vs. other immunosuppressants (rituximab, azathioprine, mycophenolate mofetil, cyclophosphamide, or tacrolimus), and the presence of fibrosis. The 75th percentile of the OS (Q3–OS) is shown for each case.